GSK delays Japanese hair-loss treatment launch on Catalent plant problems

Suspected product tampering has put production at a French Catalent ($CTLT) plant on hold--and GlaxoSmithKline ($GSK) is paying the price. The British pharma giant has delayed the launch of hair-loss drug Zagallo in Japan while it searches for another manufacturing site. More from FiercePharma

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.